Olmesartan Medoxomil E Idroclorotiazide Teva Italia (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil E Idroclorotiazide Teva Italia, is an Angiotensin II receptor blocker (ARB) presented as a fixed‑dose combination for oral use. It treats hypertension, often in adults who require additional blood‑pressure control beyond monotherapy. GNH USA supplies Olmesartan Medoxomil E Idroclorotiazide Teva Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxomil E Idroclorotiazide Teva Italia is provided by GNH USA, a certified supplier adhering to global quality standards for pharmaceutical distribution.

Olmesartan medoxomil combined with hydrochlorothiazide is indicated for the management of high blood pressure within the renin‑angiotensin‑aldosterone system pathway.

- Hypertension: lowers systolic and diastolic blood pressure when monotherapy is insufficient. - Hypertensive patients with fluid retention: adds diuretic effect to improve volume control. - Cardiovascular risk reduction: contributes to lower risk of stroke and myocardial infarction by maintaining target blood‑pressure levels.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Fatigue. - Increased urination. - Electrolyte disturbances (e.g., low potassium). - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension. - Acute kidney injury. - Hyperkalemia or severe electrolyte imbalance. - Angio‑edema. - Liver function abnormalities. - Blood cell disorders such as neutropenia.

Before initiating therapy, consider patient‑specific factors and monitor appropriately.

- Renal impairment: adjust monitoring of kidney function and electrolytes. - Hepatic disease: use with caution and observe liver enzymes. - Electrolyte balance: monitor potassium and sodium levels regularly. - Pregnancy: avoid use; teratogenic risk is not established. - Concomitant diuretics: assess for additive electrolyte loss. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmesartan medoxomil/hydrochlorothiazide may interact with several drug classes; clinical judgment is required.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): increased risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - NSAIDs (high dose): may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Lithium: increased lithium levels, risk of toxicity. - ACE inhibitors or other ARBs: additive hypotensive effect. - Antifungal azoles (e.g., ketoconazole): may increase olmesartan plasma concentrations.